The emerging role of RUNX3 in cancer metastasis (Review)

Oncology Reports

Volumn 35, Issue 3, 2016, Pages 1227-1236

  Chen, Feifei ^a   Liu, Xin ^a   Bai, Jin ^a   Pei, Dongsheng ^a   Zheng, Junnian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Cancer; Epithelial to mesenchymal transition; Metastasis; RUNX3

Indexed keywords

BETA CATENIN; MICRORNA; PROTEIN P53; RAS PROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX3; VASCULOTROPIN; WNT PROTEIN; RUNX3 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; AUTOPHAGY; CELL INVASION; CELL MIGRATION; HISTONE METHYLATION; HUMAN; METASTASIS; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; RUNX3 GENE; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; CARCINOGENESIS; CELL MOTION; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; NEOPLASM; PATHOLOGY; TUMOR INVASION;

APOPTOSIS; CARCINOGENESIS; CELL MOVEMENT; CORE BINDING FACTOR ALPHA 3 SUBUNIT; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84955490639     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4515     Document Type: Review

References (106)

1. Gupta GP and Massagué J: Cancer metastasis: Building a framework. Cell 127: 679-695, 2006.
2. Steeg PS: Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med 12: 895-904, 2006.
3. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A and Muschel RJ: Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: A new model for metastasis. Nat Med 6: 100-102, 2000.
4. Fidler IJ: The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.
5. Fukushima-Nakase Y, Naoe Y, Taniuchi I, Hosoi H, Sugimoto T and Okuda T: Shared and distinct roles mediated through C-terminal subdomains of acute myeloid leukemia/Runt-related transcription factor molecules in murine development. Blood 105: 4298-4307, 2005.
6. Wotton S, Terry A, Kilbey A, Jenkins A, Herzyk P, Cameron E and Neil JC: Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene 27: 5856-5866, 2008.
7. Brady G and Farrell PJ: RUNX3-mediated repression of RUNX1 in B cells. J Cell Physiol 221: 283-287, 2009.
8. Fukamachi H and Ito K: Growth regulation of gastric epithelial cells by Runx3. Oncogene 23: 4330-4335, 2004.
9. Levanon D, Bettoun D, Harris-Cerruti C, Woolf E, Negreanu V, Eilam R, Bernstein Y, Goldenberg D, Xiao C, Fliegauf M, et al: The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. EMBO J 21: 3454-3463, 2002.
10. Woolf E, Brenner O, Goldenberg D, Levanon D and Groner Y: Runx3 regulates dendritic epidermal T cell development. Dev Biol 303: 703-714, 2007.
11. Bagchi A and Mills AA: The quest for the 1p36 tumor suppressor. Cancer Res 68: 2551-2556, 2008.
12. Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K and Salto-Tellez M: Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta 1796: 315-331, 2009.
13. Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K, Ito Y, Chayama K and Yasui W: Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. Pathobiology 71: 137-143, 2004.
14. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, et al: RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66: 6512-6520, 2006.
15. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E and Lothe RA: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer 7: 94, 2008.
16. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, et al: RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 65: 7743-7750, 2005.
17. Voon DC, Wang H, Koo JK, Nguyen TA, Hor YT, Chu YS, Ito K, Fukamachi H, Chan SL, Thiery JP, et al: Runx3 protects gastric epithelial cells against epithelial-mesenchymal transitioninduced cellular plasticity and tumorigenicity. Stem Cells 30: 2088-2099, 2012.
18. Chen F, Bai J, Li W, Mei P, Liu H, Li L, Pan Z, Wu Y and Zheng J: RUNX3 suppresses migration, invasion and angiogenesis of human renal cell carcinoma. PLoS One 8: e56241, 2013.
19. Sakakura C, Hasegawa K, Miyagawa K, Nakashima S, Yoshikawa T, Kin S, Nakase Y, Yazumi S, Yamagishi H, Okanoue T, et al: Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin Cancer Res 11: 6479-6488, 2005.
20. Yano T, Ito K, Fukamachi H, Chi XZ, Wee HJ, Inoue K, Ida H, Bouillet P, Strasser A, Bae SC, et al: The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis. Mol Cell Biol 26: 4474-4488, 2006.
21. Peng Z, Wei D, Wang L, Tang H, Zhang J, Le X, Jia Z, Li Q and Xie K: RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer. Clin Cancer Res 12: 6386-6394, 2006.
22. Mei PJ, Bai J, Liu H, Li C, Wu YP, Yu ZQ and Zheng JN: RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration. J Cancer Res Clin Oncol 137: 1823-1830, 2011.
23. Zhang Z, Chen G, Cheng Y, Martinka M and Li G: Prognostic significance of RUNX3 expression in human melanoma. Cancer 117: 2719-2727, 2011.
24. Chen F, Wang M, Bai J, Liu Q, Xi Y, Li W and Zheng J: Role of RUNX3 in suppressing metastasis and angiogenesis of human prostate cancer. PLoS One 9: e86917, 2014.
25. Chen W, Salto-Tellez M, Palanisamy N, Ganesan K, Hou Q, Tan LK, Sii LH, Ito K, Tan B, Wu J, et al: Targets of genome copy number reduction in primary breast cancers identified by integrative genomics. Genes Chromosomes Cancer 46: 288-301, 2007.
26. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, et al: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518-527, 2008.
27. Sakakura C, Miyagawa K, Fukuda KI, Nakashima S, Yoshikawa T, Kin S, Nakase Y, Ida H, Yazumi S, Yamagishi H, et al: Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis. Oncogene 26: 5927-5938, 2007.
28. Chuang LS and Ito Y: RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 29: 2605-2615, 2010.
29. Yu YY, Chen C, Kong FF and Zhang W: Clinicopathological significance and potential drug target of RUNX3 in breast cancer. Drug Des Devel Ther 8: 2423-2430, 2014.
30. Wang D, Cui W, Wu X, Qu Y, Wang N, Shi B and Hou P: RUNX3 site-specific hypermethylation predicts papillary thyroid cancer recurrence. Am J Cancer Res 4: 725-737, 2014.
31. Katayama Y, Takahashi M and Kuwayama H: Helicobacter pylori causes runx3 gene methylation and its loss of expression in gastric epithelial cells, which is mediated by nitric oxide produced by macrophages. Biochem Biophys Res Commun 388: 496-500, 2009.
32. Cheng AS, Culhane AC, Chan MW, Venkataramu CR, Ehrich M, Nasir A, Rodriguez BA, Liu J, Yan PS, Quackenbush J, et al: Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res 68: 1786-1796, 2008.
33. Fujii S, Ito K, Ito Y and Ochiai A: Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 283: 17324-17332, 2008.
34. Lee SH, Kim J, Kim WH and Lee YM: Hypoxic silencing of tumor suppressor RUNX3 by h istone modification i n gastric cancer cells. Oncogene 28: 184-194, 2009.
35. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, et al: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322: 1695-1699, 2008.
36. Lai KW, Koh KX, Loh M, Tada K, Subramaniam MM, Lim XY, Vaithilingam A, Salto-Tellez M, Iacopetta B, Ito Y, et al; Singapore Gastric Cancer Consortium: MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer 46: 1456-1463, 2010.
37. Kitago M, Martinez SR, Nakamura T, Sim MS and Hoon DS: Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. Clin Cancer Res 15: 2988-2994, 2009.
38. Goh YM, Cinghu S, Hong ET, Lee YS, Kim JH, Jang JW, Li YH, Chi XZ, Lee KS, Wee H, et al: Src kinase phosphorylates RUNX3 at tyrosine residues and localizes the protein in the cytoplasm. J Biol Chem 285: 10122-10129, 2010.
39. Kim HR, Oh BC, Choi JK and Bae SC: Pim-1 kinase phosphorylates and stabilizes RUNX3 and alters its subcellular localization. J Cell Biochem 105: 1048-1058, 2008.
40. Kim J H, C hoi J K, C inghu S , J ang J W, L ee Y S, L i YH, Goh YM, Chi XZ, Lee KS, Wee H, et al: Jab1/CSN5 induces the cytoplasmic localization and degradation of RUNX3. J Cell Biochem 107: 557-565, 2009.
41. Sheen YY, Kim MJ, Park SA, Park SY and Nam JS: Targeting the transforming growth factor signaling in cancer therapy. Biomol Ther 21: 323-331, 2013.
42. Ito Y and Miyazono K: RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr Opin Genet Dev 13: 43-47, 2003.
43. Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, Li QL, Kim HR, Cha EJ, Lee YH, Kaneda A, et al: RUNX3 suppresses gastric epithelial cell growth by inducing p21WAF1/Cip1 expression in cooperation with transforming growth factor activated SMAD. Mol Cell Biol 25: 8097-8107, 2005.
44. Yamamura Y, Lee WL, Inoue K, Ida H and Ito Y: RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells. J Biol Chem 281: 5267-5276, 2006.
45. Yao H, Ashihara E and Maekawa T: Targeting the Wnt/catenin signaling pathway in human cancers. Expert Opin Ther Targets 15: 873-887, 2011.
46. Tanaka S, Shiraha H, Nakanishi Y, Nishina S, Matsubara M, Horiguchi S, Takaoka N, Iwamuro M, Kataoka J, Kuwaki K, et al: Runt-related transcription factor 3 reverses epithelialmesenchymal transition in hepatocellular carcinoma. Int J Cancer 131: 2537-2546, 2012.
47. Ito K, Lim AC, Salto-Tellez M, Motoda L, Osato M, Chuang LS, Lee CW, Voon DC, Koo JK, Wang H, et al: RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14: 226-237, 2008.
48. Ju X, Ishikawa TO, Naka K, Ito K, Ito Y and Oshima M: Contextdependent activation of Wnt signaling by tumor suppressor RUNX3 in gastric cancer cells. Cancer Sci 105: 418-424, 2014.
49. Palmero I, Pantoja C and Serrano M: p19ARF links the tumour suppressor p53 to Ras. Nature 395: 125-126, 1998.
50. Lee KS, Lee YS, Lee JM, Ito K, Cinghu S, Kim JH, Jang JW, Li YH, Goh YM, Chi XZ, et al: Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer. Oncogene 29: 3349-3361, 2010.
51. Kruse JP and Gu W: Modes of p53 regulation. Cell 137: 609-622, 2009.
52. Chi XZ, Kim J, Lee YH, Lee JW, Lee KS, Wee H, Kim WJ, Park WY, Oh BC, Stein GS, et al: Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination. Cancer Res 69: 8111-8119, 2009.
53. Efeyan A and Serrano M: p53: Guardian of the genome and policeman of the oncogenes. Cell Cycle 6: 1006-1010, 2007.
54. Lee YS, Lee JW, Jang JW, Chi XZ, Kim JH, Li YH, Kim MK, Kim DM, Choi BS, Kim EG, et al: Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell 24: 603-616, 2013.
55. Hnilicova J, Hozeifi S, Stejskalova E, Du.kova E, Poser I, Humpoli.kova J, Hof M and Stan.k D: The C-terminal domain of Brd2 is important for chromatin interaction and regulation of transcription and alternative splicing. Mol Biol Cell 24: 3557.3568, 2013.
56. Jin YH, Jeon EJ, Li QL, Lee YH, Choi JK, Kim WJ, Lee KY and Bae SC: Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem 279: 29409-29417, 2004.
57. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelialmesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
58. Padua D and Massague J: Roles of TGFbeta in metastasis. Cell Res 19: 89-102, 2009.
59. Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15: 178-196, 2014.
60. Lee JM, Shin JO, Cho KW, Hosoya A, Cho SW, Lee YS, Ryoo HM, Bae SC and Jung HS: Runx3 is a crucial regulator of alveolar differentiation and lung tumorigenesis in mice. Differentiation 81: 261-268, 2011.
61. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH , et al: p53 regulates epithelialmesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 13: 317-323, 2011.
62. Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, Papotti M and Allgayer H: MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer 130: 2044-2053, 2012.
63. Yamasaki T, Seki N, Yamada Y, Yoshino H, Hidaka H, Chiyomaru T, Nohata N, Kinoshita T, Nakagawa M and Enokida H: Tumor suppressive microRNA.138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma. Int J Oncol 41: 805-817, 2012.
64. Cheng CW, Wang HW, Chang CW, Chu HW, Chen CY, Yu JC, Chao JI, Liu HF, Ding SL and Shen CY: MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. Breast Cancer Res Treat 134: 1081-1093, 2012.
65. Liu Z, Chen L, Zhang X, Xu X, Xing H, Zhang Y, Li W, Yu H, Zeng J and Jia J: RUNX3 regulates vimentin expression via miR-30a during epithelial-mesenchymal transition in gastric cancer cells. J Cell Mol Med 18: 610-623, 2014.
66. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
67. Nishida N, Yano H, Nishida T, Kamura T and Kojiro M: Angiogenesis in cancer. Vasc Health Risk Manag 2: 213-219, 2006.
68. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
69. Jain RK: Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 26: 605-622, 2014.
70. Yang M, Kuang X, Pan Y, Tan M, Lu B, Lu J, Cheng Q and Li J: Clinicopathological characteristics of vascular endothelial growth factor expression in uveal melanoma: A meta-analysis. Mol Clin Oncol 2: 363-368, 2014.
71. Lee JM, Lee DJ, Bae SC and Jung HS: Abnormal liver differentiation and excessive angiogenesis in mice lacking Runx3. Histochem Cell Biol 139: 751-758, 2013.
72. Lee JM, Kwon HJ, Lai WF and Jung HS: Requirement of Runx3 in pulmonary vasculogenesis. Cell Tissue Res 356: 445-449, 2014.
73. Semenza GL: Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 54: 17-28, 2003.
74. Harris AL: Hypoxia-A key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
75. Lee SH, Bae SC, Kim KW and Lee YM: RUNX3 inhibits hypoxia-inducible factor-1α protein stability by interacting with prolyl hydroxylases in gastric cancer cells. Oncogene 33: 1458-1467, 2014.
76. Meng S, Cao J, Zhang X, Fan Y, Fang L, Wang C, Lv Z, Fu D and Li Y: Downregulation of microRNA-130a contributes to endothelial progenitor cell dysfunction in diabetic patients via its target Runx3. PLoS One 8: e68611, 2013.
77. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF and Groom AC: Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153: 865-873, 1998.
78. Nagasaka A, Kawane K, Yoshida H and Nagata S: Apaf-1-independent programmed cell death in mouse development. Cell Death Differ 17: 931-941, 2010.
79. Burgess DJ: Apoptosis: Refined and lethal. Nat Rev Cancer 13: 79, 2013.
80. Nakanishi Y, Shiraha H, Nishina S, Tanaka S, Matsubara M, Horiguchi S, Iwamuro M, Takaoka N, Uemura M, Kuwaki K, et al: Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis. BMC Cancer 11: 3, 2011.
81. Zhai FX, Liu XF, Fan RF, Long ZJ, Fang ZG, Lu Y, Zheng YJ and Lin DJ: RUNX3 is involved in caspase-3-dependent apoptosis induced by a combination of 5-aza-CdR and TSA in leukaemia cell lines. J Cancer Res Clin Oncol 138: 439-449, 2012.
82. Liu Z, Zhang X, Xu X, Chen L, Li W, Yu H, Sun Y, Zeng J and Jia J: RUNX3 inhibits survivin expression and induces cell apoptosis in gastric cancer. Eur J Cell Biol 93: 118-126, 2014.
83. Meng X, Franklin DA, Dong J and Zhang Y: MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res 74: 7161-7167, 2014.
84. Yamada C, Ozaki T, Ando K, Suenaga Y, Inoue K, Ito Y, Okoshi R, Kageyama H, Kimura H, Miyazaki M, et al: RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53. J Biol Chem 285: 16693-16703, 2010.
85. Lai CB and Mager DL: Role of runt-related transcription factor 3 (RUNX3) in transcription regulation of natural cytotoxicity receptor 1 (NCR1/NKp46), an activating natural killer (NK) cell receptor. J Biol Chem 287: 7324-7334, 2012.
86. Levanon D, Negreanu V, Lotem J, Bone KR, Brenner O, Leshkowitz D and Groner Y: Transcription factor Runx3 regulates interleukin-15-dependent natural killer cell activation. Mol Cell Biol 34: 1158-1169, 2014.
87. Zhang Y, Lu Q and Cai X: MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Lett 587: 3069-3075, 2013.
88. Li Q, Wang JX, He YQ, Feng C, Zhang XJ, Sheng JQ and Li PF: MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain. Cell Death Dis 5: e1197, 2014.
89. Boya P, Reggiori F and Codogno P: Emerging regulation and functions of autophagy. Nat Cell Biol 15: 713-720, 2013.
90. Kenific CM, Thorburn A and Debnath J: Autophagy and metastasis: Another double-edged sword. Curr Opin Cell Biol 22: 241-245, 2010.
91. Xu Q, Meng S, Liu B, Li MQ, Li Y, Fang L and Li YG: MicroRNA-130a regulates autophagy of endothelial progenitor cells through Runx3. Clin Exp Pharmacol Physiol 41: 351-357, 2014.
92. Denhardt DT, Lopez CA, Rollo EE, Hwang SM, An XR and Walther SE: Osteopontin-induced modifications of cellular functions. Ann NY Acad Sci 760: 127-142, 1995.
93. Anborgh PH, Mutrie JC, Tuck AB and Chambers AF: Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med 14: 2037-2044, 2010.
94. Fong YC, Liu SC, Huang CY, Li TM, Hsu SF, Kao ST, Tsai FJ, Chen WC, Chen CY and Tang CH: Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/ FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 64: 263-270, 2009.
95. Wang Y, Yan W, Lu X, Qian C, Zhang J, Li P, Shi L, Zhao P, Fu Z, Pu P, et al: Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avβ3/PI3K/AKT/ eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol 90: 642-648, 2011.
96. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF and Harris JF: Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3: 605-611, 1997.
97. Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Hölscher AH and Danenberg PV: Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 10: 1588-1596, 2004.
98. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T and Tahara E: Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 79: 127-132, 1998.
99. Cheng HC, Liu YP, Shan YS, Huang CY, Lin FC, Lin LC, Lee L, Tsai CH, Hsiao M and Lu PJ: Loss of RUNX3 increases osteopontin expression and promotes cell migration in gastric cancer. Carcinogenesis 34: 2452-2459, 2013.
100. Min KW, Kim DH, Do SI, Kim K, Lee HJ, Chae SW, Sohn JH, Pyo JS, Oh YH, Kim WS, et al: Expression patterns of stromal MMP-2 and tumoural MMP-2 and-9 are significant prognostic factors in invasive ductal carcinoma of the breast. APMIS 122: 1196-1206, 2014.
101. Stellas D and Patsavoudi E: Inhibiting matrix metalloproteinases, an old story with new potentials for cancer treatment. Anticancer Agents Med Chem 12: 707-717, 2012.
102. Galis ZS and Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 90: 251-262, 2002.
103. Zuo JH, Zhu W, Li MY, Li XH, Yi H, Zeng GQ, Wan XX, He QY, Li JH, Qu JQ, et al: Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell Biochem 112: 2508-2517, 2011.
104. Murphy DA and Courtneidge SA: The 'ins' and 'outs' of podosomes and invadopodia: Characteristics, formation and function. Nat Rev Mol Cell Biol 12: 413-426, 2011.
105. Bai ZK, Guo B, Tian XC, Li DD, Wang ST, Cao H, Wang QY and Yue ZP: Expression and regulation of Runx3 in mouse uterus during the peri-implantation period. J Mol Histol 44: 519-526, 2013.
106. Jinga DC, Blidaru A, Condrea I, Ardeleanu C, Dragomir C, Szegli G, Stefanescu M and Matache C: MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: Correlations with prognostic factors. J Cell Mol Med 10: 499-510, 2006.